Investment in new premises in London reflects significant milestone in Company’s growth, following $20 million Series B financing
Supports rapid scale-up and development of foundational AI imaging model, to improve clinical trial design across broader range of chest diseases
Cambridge, UK, 19 August 2026 – Qureight, an end-to-end imaging company that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, today announced the opening of its new office space in London, UK. The expansion into a second site will accommodate the…
Amsbio has launched a range of synthetic cell mimic products that eliminate the variability, fragility, and operational inefficiency inherent in traditional flow cytometry biological and polystyrene bead controls.
Researchers in pharmaceutical companies, biotechnology firms, CRO’s, clinical diagnostics and academic centres have long sought access to mass-produced cell mimics that contain rare biomarkers and are stable over the long term for the development of targeted therapies.
Benefitting from unmatched lot-to-lot consistency with coefficients of variation as low as 0.1%…
Cambridge UK: 18 August 2026
Penningtons Manches Cooper has renewed its partnership with One Nucleus. The One Nucleus Partner Programme is tailor-made to meet the needs of the One Nucleus Members, the Partner and One Nucleus in delivering on its core remit of supporting innovation.
Rachel Bradley, Partner at Penningtons Manches Cooper commented:
"Our long-standing relationship with One Nucleus reflects our shared commitment to supporting the success of innovative life sciences businesses. We are pleased to renew our partnership and continue engaging with a community that is driving…
Welcome to the Q3 Edition of Our People Pathways Newsletter!
This edition brings together the latest opportunities, support and resources from across the One Nucleus network. From upcoming courses, seminars and webinars to mentoring opportunities, career support and our new Job Seeker Membership, there’s plenty to explore. We’ve also included useful connections, industry resources and updates to help you keep learning, build your network and stay connected to the life science community.
____________________________________________________________
One Nucleus Upcoming Learning…
Supporting laboratories through IVDR transition
Clinical cytogenetics laboratories in the EU and other IVDR-aligned markets are under increasing pressure to maintain compliant, validated workflows while managing the practical impact of their portfolio transition. OGT’s IVDR programme is designed to help customers maintain continuity across the CytoCell portfolio, backed by a dedicated team of clinical and technical FISH specialists.
OGT has long offered a comprehensive CE marked under IVDD portfolio and was the first manufacturer of FISH probes to obtain the new IVDR certification on its…
Utilising enzyme-free DNA nanotechnology, immunoMUSE® kits from Amsbio enable researchers to perform ultra-sensitive, 2-plex to 4-plex custom biomarker detection in tissue while generating same-day imaging results without species or isotype constraints.
Traditionally, tissue immunofluorescence techniques have required compromises. Researchers working with FFPE tissue, low-abundance biomarkers, and complex immune environments have typically had to choose between sensitivity, workflow complexity, and panel flexibility. Often repeated staining cycles have risked…
Grant funding delivered in partnership with the NC3Rs, in support of UK Government roadmap to reduce animal testing by 2030
Project to develop standardized workflow to more accurately predict drug behaviors, reduce animal testing and streamline development of safer, more effective medicines
Cambridge, UK, 12 August 2026: CN Bio, a leading provider of Organ-on-a-chip (OOC) Systems and solutions that accelerate drug discovery and development workflows, today announced it has been awarded £180k grant funding from Innovate UK. Delivered in partnership with the National Centre for…
A new funded programme will support start-ups applying structural chemistry data, AI and machine learning to solve real-world scientific challenges
The Cambridge Crystallographic Data Centre (CCDC) today announced the launch of the CCDC Innovation Fund, a new seed funding programme designed to support emerging companies developing innovative solutions in structural chemistry.
The fund, backed by an initial commitment from the CCDC of up to £300,000, will provide early-stage support to start-ups and university spin-outs seeking to transform structural chemistry research into impactful…
As life sciences businesses balance growth ambitions with tighter budgets, the value of industry events is under increasing scrutiny. Organisations still need to connect with customers, collaborators and peers, but they also need confidence that each event delivers a clear return for the time and money invested.We asked CEO Geoff Davison to explain why Bionow's events programme continues to grow across the North of the UK, with more than 35 events delivered to over 2,500 attendees in 2025. He discusses how the programme delivers exceptional value compared with many larger conferences, and why…
· Extension of the INDUCE-seq platform to support adenine base editing (ABE) workflows
· Researchers invited to gain early access to platform and support ongoing product development
Cambridge, UK, 10 August 2026 – Broken String Biosciences, a biotechnology company enabling gene editing teams to accelerate development of safer, more effective genetic medicines, today announced the launch of BaseMap™ ABE. Built on the Company's INDUCE-seq® technology, BaseMap ABE extends the platform's capabilities to…